Show simple item record

dc.contributor.authorKerkmeijer, LGWen_US
dc.contributor.authorFuller, CDen_US
dc.contributor.authorVerkooijen, HMen_US
dc.contributor.authorVerheij, Men_US
dc.contributor.authorChoudhury, Aen_US
dc.contributor.authorHarrington, KJen_US
dc.contributor.authorSchultz, Cen_US
dc.contributor.authorSahgal, Aen_US
dc.contributor.authorFrank, SJen_US
dc.contributor.authorGoldwein, Jen_US
dc.contributor.authorBrown, KJen_US
dc.contributor.authorMinsky, BDen_US
dc.contributor.authorvan Vulpen, Men_US
dc.contributor.authorMR-Linac Consortium Clinical Steering Committeeen_US
dc.date.accessioned2017-09-06T10:53:58Z
dc.date.accessioned2017-09-07T15:24:56Z
dc.date.issued2016-01en_US
dc.identifier.citationFrontiers in oncology, 2016, 6 pp. 215 - ?en_US
dc.identifier.issn2234-943Xen_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/815
dc.identifier.eissn2234-943Xen_US
dc.identifier.doi10.3389/fonc.2016.00215en_US
dc.description.abstractAn international research consortium has been formed to facilitate evidence-based introduction of MR-guided radiotherapy (MR-linac) and to address how the MR-linac could be used to achieve an optimized radiation treatment approach to improve patients' survival, local, and regional tumor control and quality of life. The present paper describes the organizational structure of the clinical part of the MR-linac consortium. Furthermore, it elucidates why collaboration on this large project is necessary, and how a central data registry program will be implemented.en_US
dc.formatElectronic-eCollectionen_US
dc.format.extent215 - ?en_US
dc.languageengen_US
dc.language.isoengen_US
dc.relation.replaceshttps://repository.icr.ac.uk/handle/internal/812
dc.relation.replacesinternal/812
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.subjectMR-Linac Consortium Clinical Steering Committeeen_US
dc.titleThe MRI-Linear Accelerator Consortium: Evidence-Based Clinical Introduction of an Innovation in Radiation Oncology Connecting Researchers, Methodology, Data Collection, Quality Assurance, and Technical Development.en_US
dc.typeJournal Article
dcterms.dateAccepted2016-09-28en_US
rioxxterms.versionofrecord10.3389/fonc.2016.00215en_US
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0en_US
rioxxterms.licenseref.startdate2016-01en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfFrontiers in oncologyen_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.publication-statusPublisheden_US
pubs.volume6en_US
pubs.embargo.termsNot knownen_US
icr.researchteamTargeted Therapyen_US
dc.contributor.icrauthorHarrington, Kevinen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/